Compare Cytokinetics Inc (CYTK) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Marsh & McLennan Companies, Inc. trades at $181.62 (market cap $85.78B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 7.7× Cytokinetics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.22% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MRSH | |
|---|---|---|
Market Cap | $11.12B | $85.78B |
Sector | Technology | Financials |
52-Week High | $87.26 | $212.28 |
52-Week Low | $33.23 | $157.32 |
Enterprise Value | $11.59B | $106.62B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Marsh (MRSH) trades at $181.53, up 1.81% with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations. Revenue grew to $26.98B in 2025 with a 14.26% net margin, while recent dividend increases and strategic acquisitions highlight management's confidence in cash flow generation.
The stock presents a balanced outlook with 33% analyst buy ratings and a $203.67 consensus target offering 12% upside. However, elevated valuation ratios and bearish oscillators suggest near-term consolidation risk. Key catalysts include Q2 2026 earnings and sustained organic growth amid easing insurance pricing headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
